Table 2.
Disease Characteristics for Respondents With MPNs Employed at Diagnosis
| MF (n = 174) | PV (n = 248) | ET (n = 170) | All MPNs (n = 592) | |
|---|---|---|---|---|
| Duration of disease, mean (SD), y | 4.6 (4.7) | 6.9 (7.2) | 6.3 (6.4) | 6.1 (6.4) |
| Risk score at any time during treatment | ||||
| High | 25 (14.4) | 35 (14.1) | 41 (24.1) | 101 (17.1) |
| Intermediate | 61 (35.1) | 29 (11.7) | 21 (12.4) | 111 (18.8) |
| Low | 17 (9.8) | 22 (8.9) | 34 (20.0) | 73 (12.3) |
| Not available or did not recall | 71 (40.8) | 162 (65.3) | 74 (43.5) | 307 (51.9) |
| Comorbid conditions ever diagnosed* | ||||
| Diabetes | 28 (16.1) | 21 (8.5) | 9 (5.3) | 58 (9.8) |
| Solid tumor | 13 (7.5) | 12 (4.8) | 9 (5.3) | 34 (5.7) |
| Emphysema or COPD | 9 (5.2) | 13 (5.2) | 5 (2.9) | 27 (4.6) |
| Connective tissue disorders | 8 (4.6) | 8 (3.2) | 10 (5.9) | 26 (4.4) |
| Moderate to severe kidney disease | 13 (7.5) | 8 (3.2) | 3 (1.8) | 24 (4.1) |
| Liver disease | 7 (4.0) | 9 (3.6) | 4 (2.4) | 20 (3.4) |
| History of thrombotic events,† n (%) | 40 (23.0) | 51 (20.6) | 37 (21.8) | 128 (21.6) |
COPD, chronic obstructive pulmonary disease; ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythemia vera
*Occurring in > 3% of all respondents employed at diagnosis
†Each respondent could have > 1 thrombotic event